Reema Zeineldin, Ph.D.
Advantages of targeting:
Reduces nonspecific cytotoxicity
Selectively direct nanocarriers to specific endocytic compartments or intracellular organelles
Design linkers to release drugs in the endosome to which the nanocarrier is directed
Application to therapy of cancers expressing certain receptors
Candidate receptors in ovarian cancer:
Epidermal growth factor receptor
Folate receptor alpha